CliffBio
small molecule

PERINDOPRIL ERBUMINE

PERINDOPRIL ERBUMINE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand namePERINDOPRIL ERBUMINE
Active ingredientPERINDOPRIL ERBUMINE
Strength2MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2010
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.